Helicobacter Pylori Infection
Conditions
Keywords
helicobacter pylori, saliva microbiota
Brief summary
Helicobacter pylori (H. pylori), a bacteria transmitted from human to human through upper digestive tract as well as fecal-oral transmission, had infected more than half of people around the world. However, the quantity of H. pylori in oral cavity and its influence on oral microbiota remains to be unclear. The aim of the present study was to examine the effects of H. pylori infection as well as its eradication on oral microbiota.
Interventions
DRUGEsomeprazole
Proton pump inhibitor
DRUGAmoxicillin
Antibiotics for H. pylori eradication
DRUGBismuth Potassium Citrate
Gastric mucosal protective drug with anti-H. pylori effect
Sponsors
Shanghai Jiao Tong University School of Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Participants with non-ulcer functional dyspepsia or peptic ulcer disease * Ability and willingness to participate in the study and to sign and give informed consent * Received both endoscopy and 13C urea breath test (13C-UBT) before enrolled
Exclusion criteria
* Less than 18 years old * With previous gastric surgery * Major systemic diseases * Pregnancy or lactation * Allergy to any of the study drugs Administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to inclusion * The use of antibiotics or PPI within 2 months before the study * The presence of dental carious or any untreated cavitated carious lesions and oral abscesses
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change of saliva microbiota after eradication | Two months after completion of therapy. | Two months after completion of therapy, saliva microbiota was assessed by 16S rDNA Pyrosequencing. |
Countries
China
Contacts
Primary ContactYingjie Ji, M.D.
Outcome results
None listed